Bicyclic Nitrogen Compounds Modulating CXCR4 and CCXCKR2 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CXCR4-mediated diseases, such as cancer and HIV, lack effective small molecule inhibitors that can modulate the binding and signaling effects of SDF-1 to the CXCR4 receptor, and there is a need for compounds that can specifically target the CCXCKR2 receptor to treat related conditions.
Innovation Solution
Development of compounds with a specific formula that can bind to the CXCR4 and CCXCKR2 receptors, preventing the interaction with their respective ligands, SDF-1 and I-TAC, to modulate their signaling and chemotactic effects, thereby treating CXCR4- and CCXCKR2-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to block CXCR4 and CCXCKR2 receptors, then therapeutic effectiveness against cancer and HIV is improved, but the complexity of drug design and development increases
Solution Approach 1:
The patent divides the therapeutic target into two separate receptor types (CXCR4 and CCXCKR2) that can be addressed by compounds with similar but distinct structural features. The bicyclic core structure serves as a common segment that can be modified with different substituents to target each receptor specifically, allowing systematic optimization of therapeutic effectiveness for each indication.
Solution Approach 2:
The patent develops a universal bicyclic compound scaffold that can function as an inhibitor for both CXCR4 and CCXCKR2 receptors. By designing a core structure with variable substituent positions (R1-R6) and types, the invention creates a multi-functional platform that addresses multiple therapeutic indications (cancer, HIV) through a single chemical series, reducing overall development complexity.
2Object-affected harmful factors
If compounds are designed to specifically bind to CXCR4 and CCXCKR2 receptors, then selectivity and reduced off-target effects are improved, but the difficulty of achieving specific binding increases
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions (R1-R6) on the bicyclic core structure. Different substituent combinations create localized chemical properties that enhance binding affinity and selectivity for specific receptor subtypes, allowing differentiation between CXCR4 and CCXCKR2 interactions through targeted molecular modifications.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent type (halogen, alkyl, aryl, heteroaryl), substituent position (R1-R6), and molecular geometry to optimize receptor binding specificity. By changing these chemical parameters across a series of related compounds, the invention achieves selective binding to desired receptors while minimizing off-target effects.
Data Source
AI summary
The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.